Adjuvant therapy in pancreatic cancer

doi:10.3748/wjg.v20.i40.14733

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 40

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7115)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

453

WORD

234

HTML

3756

Tables (1-5)

206

Sum=4649

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1272

Download

1194

Sum=2466

Oct 28, 2014 (publication date) through Dec 20, 2024

Times Cited of This Article

Times Cited (28)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 28, 2014; 20(40): 14733-14746
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14733

Adjuvant therapy in pancreatic cancer

Owain Peris Jones, James Daniel Melling, Paula Ghaneh

Owain Peris Jones, James Daniel Melling, Paula Ghaneh, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 5^th Floor UCD Building, Daulby Street, Liverpool L69 3GA, United Kingdom

Author contributions: All three authors contributed to the literature search, writing and editing of this manuscript.

Correspondence to: Paula Ghaneh, Professor, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 5^th Floor UCD Building, Daulby Street, Liverpool L69 3GA, United Kingdom. p.ghaneh@liverpool.ac.uk

Telephone: +44-151-7064170 Fax: +44-151-7065826

Received: February 26, 2014
Revised: April 29, 2014
Accepted: May 25, 2014
Published online: October 28, 2014
Processing time: 245 Days and 14.1 Hours

Abstract

Pancreatic cancer remains one of the leading causes of cancer related death worldwide with an overall five-year survival of less than 5%. Potentially curative surgery, which alone can improve 5-year survival to 10%, is an option for only 10%-20% of patients at presentation owing to local invasion of the tumour or metastatic disease. Adjuvant chemotherapy has been shown to improve 5-year survival to 20%-25% but conflicting evidence remains with regards to chemoradiation. In this article we review the current evidence available from published randomised trials and discuss ongoing phase III trials in relation to adjuvant therapy in pancreatic cancer.

Keywords: Pancreatic cancer; Adjuvant; Gemcitabine; Chemotherapy; Chemoradiotherapy; Phase III

Core tip: This paper discusses every major trial undertaken in the field of adjuvant therapy in pancreatic cancer. The evolution of chemotherapeutic regimes over the past 25 years and the controversy surrounding chemoradiation are analysed, in addition to looking at the phase III trials currently in progress.